Printer Friendly

HEMOSOL AND DUTCH RED CROSS TO COLLABORATE ON RESEARCH AND DEVELOPMENT OF HUMAN BLOOD SUBSTITUTE PRODUCT

 ETOBICOKE, Ontario, Aug. 3 /PRNewswire/ -- Two of the leading developers of human blood substitute products have decided to pool their expertise to accelerate their research and development programs.
 In a joint announcement today, Hemosol Inc. of Toronto and the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB) in Amsterdam will collaborate on the research and development of cross-linked hemoglobin solutions. The agreement provides CLB and Hemosol with reciprocal non-exclusive rights to each other's technology for R & D purposes.
 In addition, both groups will exchange information and advice regarding regulatory, clinical and patent strategies.
 Alun Davies, Hemosol's president and chief executive officer, said this agreement provides complementary advantages to both parties. "We will no doubt benefit from CLB's expertise in clinical research and the regulatory processes in Europe, and their skill in manufacturing blood products. It is an extremely good fit."
 Dr. Joost Ruitenberg, CLB's Director with responsibility for research, said "Hemosol's expertise in protein chemistry, allied with CLB's strength in physiology and clinical research, will provide significant synergy to both programs. We anticipate that each program will be substantially enhanced by the collaboration."
 The CLB has, for many years, been a leading European center for research, collection and manufacturing of human blood products. Their expanded plasma fractionation facility is expected to be brought on stream later in 1993. The CLB blood substitute program has received considerable support and financial backing from the Dutch military authorities.
 Hemosol's first technology involves the cross-linking and oligomerization of human hemoglobin with oxidized raffinose, a complex sugar molecule. Additional cross-linking technologies in which Hemosol is involved include those based on acyl phosphate esters. Earlier in May, Hemosol began production of its initial blood substitute product, Hemolink(TM), for pre-clinical studies and Phase I and Phase II clinical trials. These clinical studies are planned for early next year.
 -0- 8/3/93
 /CONTACT: Alun Davies, president and chief executive officer, 416-798-0700, or Dr. Anthony Magnin, vice president, operations and scientific affairs, 416-798-0700, or (fax) 416-798-0151 or Dr. Joost Ruitenberg, general and scientific director, Central Laboratory of the Netherlands Red Cross, Blood Transfusion Service, 31-20 512 3224, or (fax) 31-20-512-3252/
 (HML.)


CO: Hemosol Inc. ST: Ontario IN: MTC SU:

TS -- NY018 -- 8752 08/03/93 09:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1993
Words:374
Previous Article:GOLIATH MARVEL FILES LAWSUIT AGAINST DEFIANT DAVID -- ELEVENTH HOUR ATTEMPT TO STOP FAST START OF COMIC RIVAL --
Next Article:FILA HOLDING S.P.A. ANNOUNCES ITS CONSOLIDATED RESULTS FOR THE QUARTER ENDED JUNE 30, 1993
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters